Phase III results of PROSPECT study for metastatic, castration-resistant prostate cancer

Targeting AR in Castration Resistant Prostate CancerПодробнее

Phase 3 VISION Study of 177LuPSMA 617 for Metastatic Castration-Resistant Prostate CancerПодробнее

Expert Video Report on castration sensitive and resistant prostate cancer - 2021 ASCO Annual MeetingПодробнее

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?Подробнее

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancerПодробнее

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prosta...Подробнее

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022Подробнее

Expert Video Viewpoints on Castration-Resistant Prostate Cancer - Section 3Подробнее

Comparing real world evidence to phase III data on apalutamide for nmCRPCПодробнее

Castration Resistant Prostate Cancer - Developments and Challenges from 2020Подробнее

Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate CancerПодробнее

ASCO20 - PROSPER Trial Data - Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)Подробнее

Metastatic castration-resistant prostate cancer – New learnings and perspectivesПодробнее

#ESMO21 Expert Video Report on Prostate cancerПодробнее

TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPCПодробнее

ESMO 2020 Expert Video Report on precision medicine in prostate cancerПодробнее

Metastatic castration resistant prostate cancer: Updates from ASCO 2019Подробнее

Update on Mechanisms of Resistance in Castration-Resistant Prostate CancerПодробнее

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...Подробнее